In the evolving landscape of regenerative medicine, mitochondrial transplantation emerges as a startlingly promising approach. This novel concept involves isolating intact, functional mitochondria and delivering them into cells experiencing mitochondrial insufficiency. Unlike gene or stem cell therapies, mitochondrial transplantation aims to rapidly reconstitute bioenergetics without genetically altering the host cell. However, despite encouraging preliminary findings in animal and cellular models, a fundamental understanding of how transplanted mitochondria interface with recipient cells remains elusive. Do these organelles penetrate the cellular membrane and integrate functionally? If so, through which cellular uptake mechanisms? And critically, can they sustain their bioenergetic roles once internalized?

A landmark study recently addressed these pivotal questions with unprecedented rigor. Led by Associate Professor Kosuke Kusamori at Tokyo University of Science, the research employed mesenchymal stromal cells (MSCs)—a cell type renowned for regenerative potential—as recipients for isolated mitochondria. By amalgamating advanced imaging modalities—including fluorescence microscopy, confocal imaging, flow cytometry, and electron microscopy—with comprehensive biochemical assays, the investigators mapped the trajectory and function of exogenous mitochondria within MSCs. This multifaceted approach allowed precise visualization and quantification of mitochondrial uptake, as well as functional assessments post internalization.

Initial experiments focused on the isolation of mitochondria while preserving their ultrastructure and functional capacity. The mitochondria extracted from MSCs demonstrated high purity, devoid of contaminants such as other cellular organelles or debris. Importantly, these isolated mitochondria retained robust ATP synthesis ability, indicating preserved bioenergetic integrity during the isolation process. Subsequent provision of these mitochondria to living MSCs and hepatocytes yielded remarkable enhancements in cellular health. Notable outcomes included increased cell proliferation rates and improved resistance to oxidative and chemical stressors, reflecting the mitochondria’s cytoprotective effect.

A central question was whether these beneficial effects required actual mitochondrial internalization by recipient cells. Time-course studies revealed a gradual, time-dependent uptake of mitochondria by MSCs, reaching significant intracellular accumulation over several hours. Electron microscopic analysis showcased mitochondria entrapped within membrane-bound vesicles inside the cytoplasm, confirming true internalization rather than superficial adherence. By employing specific pharmacological inhibitors to block clathrin-, caveolin-, CLIC/GEEC-, and actin-mediated endocytic pathways, the research uncovered that MSCs utilize multiple, overlapping mechanisms to engulf transplanted mitochondria. This multiplicity underscores a complex, multifaceted cellular uptake process differing from single-pathway endocytosis found in many other biological processes.

Functional assays corroborated that the internalized mitochondria remained bioenergetically active. MSCs receiving mitochondrial transplants demonstrated enhanced mitochondrial respiration, evaluated by oxygen consumption rate measurements, alongside increased ATP production. These effects displayed a dose-responsive relationship to mitochondrial concentration, emphasizing the therapeutic potential of modulating mitochondrial doses. The enhanced respiratory capacity, coupled with heightened proliferation and stress resistance, suggests that transplanted mitochondria can more than simply survive within host cells—they actively improve cellular metabolic competence.

The elucidation of these uptake pathways and their biological consequences lays a crucial foundation for advancing mitochondrial transplantation from bench to bedside. By harnessing natural endocytic routes, therapeutic protocols can be optimized to maximize mitochondrial delivery efficiency. Such precision could enable tailored approaches adapted to the unique endocytic profiles of different cell types or pathological states. Moreover, confirming that transplanted mitochondria retain functionality challenges previous skepticism regarding their intracellular fate and offers compelling evidence for mitochondrial therapy as a distinct biomedical field.

Currently, mitochondrial transplantation remains in preclinical research, with many regulatory, safety, and efficacy hurdles to overcome. Long-term studies are needed to assess the persistence and integration of transplanted mitochondria, potential immune responses, and effects on tissue homeostasis across diverse disease models. Ensuring the purity, consistency, and biological activity of isolated mitochondria is paramount for clinical translation. Nonetheless, the non-genetic nature of this approach could provide rapid interventions for acute mitochondrial failure, circumventing complexities linked to gene editing or stem cell integration.

The therapeutic applications of mitochondrial transplantation are vast and especially poignant in diseases marked by mitochondrial defects. Ischemia–reperfusion injury following heart attacks or strokes, neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases, and toxin-induced hepatic injury are all promising targets. Furthermore, mitochondrial therapy could revolutionize treatment paradigms in aging—a state intimately linked to mitochondrial decline—and other chronic conditions characterized by compromised cellular energetics.

Ultimately, this innovative research represents a leap forward in regenerative medicine and cellular bioengineering. Dr. Kusamori and his team’s work provides a rigorous scientific blueprint for developing mitochondrial therapy as a novel, precise, and powerful modality to restore cellular energy homeostasis. With continued investigation and refinement, mitochondrial transplantation holds the potential to transform clinical care for a spectrum of debilitating diseases, offering hope for treatments rooted in the restoration of life’s fundamental energy processes.

—

Subject of Research: Cells
Article Title: Uptake mechanisms and functions of isolated mitochondria in mesenchymal stromal cells
News Publication Date: 29-Dec-2025
References: DOI: 10.1038/s41598-025-28494-5
Image Credits: Associate Professor Kosuke Kusamori, Tokyo University of Science, Japan
Keywords: Mitochondria, Mesenchymal stromal cells, Mitochondrial transplantation, Cellular bioenergetics, Endocytosis, Regenerative medicine, Oxidative phosphorylation, Cellular respiration, Cell proliferation, Mitochondrial therapy, Neurodegenerative diseases, Mitochondrial dysfunction

Mitochondria, often dubbed the powerhouses of the cell, rely on a sophisticated network of metabolites and cofactors to drive oxidative phosphorylation and energy generation. Central to these processes is coenzyme A, a multifaceted cofactor facilitating acyl group transfer reactions essential for fatty acid oxidation, the tricarboxylic acid (TCA) cycle, and numerous biosynthetic pathways. Despite CoA’s significance, the mechanisms by which it is transported into mitochondria—a compartment separated from the cytoplasm by a highly selective double membrane—have remained largely enigmatic. The identification and functional elucidation of SLC25A42 and SLC25A16 as mitochondrial CoA importers mark a transformational advance in mitochondrial biology.

The research team employed an innovative cellular profiling platform capable of quantifying a comprehensive spectrum of acyl-CoA species across subcellular compartments. This pan-chain acyl-CoA profiling offers unprecedented resolution into the dynamic distribution and utilization of CoA and its derivatives within cells. By integrating metabolomic data with genetic perturbations and biochemical assays, the authors systematically demonstrated that SLC25A42 and SLC25A16 are indispensable for steady-state mitochondrial CoA levels and for sustaining metabolic flux through key mitochondrial pathways.

SLC25A42, previously a relatively uncharacterized member of the solute carrier family 25 (SLC25), was revealed as a primary transporter responsible for importing CoA into the mitochondrial matrix. This transporter exhibits substrate specificity and kinetic properties tailored to facilitate efficient CoA translocation against intracellular concentration gradients. Similarly, SLC25A16 was shown to have a complementary role, potentially mediating the exchange or transport of acylated CoA derivatives, thereby ensuring the versatility of mitochondrial acyl-CoA pools necessary for diverse metabolic processes.

The implications of these findings are multifold. By elucidating the pathways controlling mitochondrial CoA homeostasis, the study provides vital insights into the pathophysiology of metabolic disorders linked to mitochondrial dysfunction, such as neurodegenerative diseases, inherited mitochondrial syndromes, and metabolic syndromes including diabetes and obesity. Disruptions in CoA metabolism may produce cascading effects on energy production, lipid metabolism, and redox balance, highlighting the therapeutic potential of targeting SLC25A42 and SLC25A16 or their regulatory networks.

A striking facet of the study is its methodological innovation. The pan-chain acyl-CoA profiling method applies advanced mass spectrometry coupled with subcellular fractionation techniques to dissect the intracellular milieu with molecular precision. This approach circumvents previous technical barriers posed by the instability and low abundance of acyl-CoAs, delivering quantitative data that unravel the complex interplay of acyl-CoA species within and across cellular compartments. This methodological leap can be readily extended to investigate metabolic alterations in diverse physiological and pathological contexts.

The study further included comprehensive characterization of how the loss or impairment of these transporters impacts mitochondrial function. Loss-of-function models demonstrated a marked depletion of mitochondrial CoA pools, leading to a cascade of metabolic deficiencies, including impaired fatty acid oxidation and disrupted energy metabolism. These deficits culminated in reduced mitochondrial respiration and compromised cellular viability under metabolically demanding conditions. These findings underscore the indispensability of SLC25A42 and SLC25A16 for maintaining mitochondrial metabolic fidelity.

Beyond mere transport functions, SLC25A42 and SLC25A16 appear to intricately modulate mitochondrial metabolic networks by governing the availability of CoA species critical for enzymatic activity. This regulation influences acylation modifications of mitochondrial proteins, thereby fine-tuning mitochondrial dynamics, biogenesis, and signaling pathways. Such revelations open new avenues for exploring mitochondrial regulation at the intersection of metabolite transport and epigenetic-like control via acylation.

This work also illuminates the evolutionary conservation and diversification of CoA transport mechanisms. Comparative analyses indicate that homologues of SLC25A proteins exist across species, suggesting a conserved fundamental role in mitochondrial function. However, variations in transporter specificity and regulation highlight the adaptive evolution catering to organismal metabolic needs and environmental cues. This insight enriches our understanding of mitochondrial specialization in different tissues and physiological states.

Crucially, the researchers point to the potential for pharmacological targeting of SLC25A42 and SLC25A16 to manipulate mitochondrial CoA levels therapeutically. Modulating these transporters could restore metabolic balance in disease contexts characterized by mitochondrial insufficiency or metabolic dysregulation. The specificity of these transporters to mitochondrial CoA import presents an attractive target with minimal off-target effects, heralding a promising frontier in mitochondrial medicine.

The data also reinforce the intricate interdependence of mitochondrial and cytoplasmic metabolism, establishing CoA transport as a nodal point linking distinct metabolic compartments. Disruption in CoA flux can reverberate through lipid synthesis, amino acid metabolism, and energy production, underscoring the necessity of a coherent regulatory framework maintaining metabolic homeostasis across organelles.

In terms of clinical translation, the findings encourage the development of diagnostic markers based on CoA transporter activity or mitochondrial acyl-CoA profiles. Such biomarkers could enhance early detection of mitochondrial dysfunction and enable monitoring of therapeutic interventions. Furthermore, the pan-chain acyl-CoA profiling technology itself holds promise as a tool for precision medicine applications, allowing customized metabolic mapping in patient-derived samples.

The study’s comprehensive approach—spanning biochemistry, cell biology, metabolomics, and molecular genetics—sets a new benchmark for investigating mitochondrial metabolite transport. It exemplifies the power of integrated multi-omics and functional assays to decode the complexities of cellular metabolism, paving the way for future discoveries in the field.

Overall, this landmark research redefines the landscape of mitochondrial coenzyme A biology by identifying and characterizing its primary importers. The insights gained provide a critical foundation for understanding how mitochondrial metabolism is orchestrated and how perturbations in this process contribute to disease. As mitochondrial dysfunction underlies a plethora of human disorders, the revelation of SLC25A42 and SLC25A16’s pivotal roles opens exciting prospects for innovative therapeutic strategies targeting cellular energy metabolism at its core.

Subject of Research: Mitochondrial coenzyme A transport and metabolism; identification and characterization of SLC25A42 and SLC25A16 as mitochondrial CoA importers.

Article Title: Cellular pan-chain acyl-CoA profiling reveals SLC25A42/SLC25A16 in mitochondrial CoA import and metabolism.

Article References:
Liu, R., Zhang, Z., Kyaw, A.K. et al. Cellular pan-chain acyl-CoA profiling reveals SLC25A42/SLC25A16 in mitochondrial CoA import and metabolism. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01358-y

Image Credits: AI Generated